Kohta Satake

Kohta Satake

Auto-generated profile, based on publicly available information

Kohta Satake

CureApp Institute Karuizawa Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2020 in npj Digital Medicine
Verified
Journal Article
Open access
KMKatsunori Masaki
Katsunori Masaki
HTHiroki Tateno
Hiroki Tateno
ANAkihiro Nomura
Akihiro Nomura
TMTomoyasu Muto
Tomoyasu Muto
SSShin Suzuki
Shin Suzuki
KFKoichi Fukunaga
Koichi Fukunaga
Evidence of the long-term efficacy of digital therapies for smoking cessation that include a smartphone application (app) is limited. In this multi-center randomized controlled trial, we tested the efficacy of a novel digital therapy for smoking cessation: the “CureApp Smoking Cessation (CASC)” system, including a CASC smartphone app, a web-based patient management PC software for primary physicians, and a mobile exhaled carbon monoxide (CO) checker. A total of 584 participants with nicotine dependence were recruited from October 2017 to January 2018, and allocated 1:1 to the CASC intervention group or the control group. Both groups received a standard smoking cessation treatment with pharmacotherapy and counseling for 12 weeks. Meanwhile, the intervention group used the CASC system, and the control group used a control-app without a mobile CO checker, each for 24 weeks. The primary outcome was the biochemically validated continuous abstinence rate (CAR) from weeks 9 to 24. The main secondary outcome was an extended CAR from weeks 9 to 52. Except for 12 participants who did not download or use the apps, 285 participants were assigned to the intervention group, and 287, to the control. CAR from weeks 9 to 24 in the intervention group was significantly higher than that in the control group (63.9% vs. 50.5%; odds ratio [OR], 1.73; 95% confidence interval [CI], 1.24 to 2.42;P = 0.001). The CAR from weeks 9 to 52 was also higher in the intervention group than that in the control group (52.3% vs. 41.5%; OR, 1.55; 95% CI, 1.11 to 2.16;P = 0.010). No specific adverse events caused by the CASC system were reported. Augmenting standard face-to-face counseling and pharmacotherapy with a novel smartphone app, the CASC system significantly improved long-term CARs compared to standard treatment and a minimally supportive control app.

26 April 2019 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ANAkihiro Nomura
Akihiro Nomura
TTTomoyuki Tanigawa
Tomoyuki Tanigawa
TMTomoyasu Muto
Tomoyasu Muto
TOTakafumi Oga
Takafumi Oga
YFYasushi Fukushima
Yasushi Fukushima
KSKohta Satake
Kohta Satake
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Tobacco is a major public health concern. A 12-week standard smoking cessation program is available in Japan; however, its required face-to-face clinic visits has been one of the key obstacles to completing the program, leading to a low smoking cessation success rate. Telemedicine using an internet-based video counseling instead of regular clinic visits could address the obstacles. Objective: This study aimed to evaluate the efficacy and feasibility of an internet-based remote smoking cessation support program compared with the standard face-to-face clinical visit program among patients with nicotine dependence. Methods: This study was a randomized, controlled, open-label, multi-center, non-inferiority trial. We recruited nicotine-dependent adults from March to June 2018. Participants randomized to the telemedicine arm underwent an internet-based video counseling, whereas control participants underwent standard face-to-face clinical visits at each time point on the smoking cessation program. Both arms received a CureApp Smoking Cessation smartphone application with a mobile exhaled carbon monoxide checker. The primary outcome was a continuous abstinence rate (CAR) at weeks 9–12. We conducted all analyses by full analysis set. Results: We randomized 115 participants with nicotine dependence: 58 were allocated to the telemedicine (internet-based video counseling) arm and 57, to the control (standard face-to-face clinical visit) arm. We analyzed all 115 participants for the primary outcome. Both telemedicine and control groups had similar CARs at weeks 9–12 (telemedicine vs. control, 81.0% vs. 78.9%; absolute difference, 2.1%; 95% confidence interval, -12.8 to 17.0); the lower limit of the difference between groups (-12.8%) was greater than a pre-specified limit (-15%). Conclusions: The application of telemedicine using internet-based video counseling as a smoking cessation program had a similar CAR at weeks 9–12 as the standard face-to-face clinical visit program. The efficacy of the telemedicine-based smoking cessation program was non-inferior to that of the standard visit-based smoking cessation program. Clinical Trial: This trial was registered at the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN ID: UMIN000031620).

19 February 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
KMKatsunori Masaki
Katsunori Masaki
HTHiroki Tateno
Hiroki Tateno
NKNaofumi Kameyama
Naofumi Kameyama
EMEriko Morino
Eriko Morino
RWRiri Watanabe
Riri Watanabe
KFKoichi Fukunaga
Koichi Fukunaga
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Mobile applications have been considered to provide active and continuous support for smoking cessation. However, it is yet to be known whether a smoking cessation smartphone application improves long-term abstinence rates in nicotine-dependent patients. Objective: We aim to evaluate the long-term abstinence effect of a novel smartphone application, CureApp Smoking Cessation (CASC), in patients with nicotine dependence. Methods: This study was a prospective, interventional, multicenter, single-arm study. We provided the CASC application to all the participants, who used it daily for 24 weeks. The CASC application includes features to maximize the therapeutic effect of pharmacological therapies and counseling at outpatient clinics for smoking cessation. The primary endpoint was a continuous abstinence rate (CAR) from weeks 9 to 24, while secondary endpoints were CARs from weeks 9 to 12 and 9 to 52. Results: Of the 56 adult smokers recruited, one did not download the application; therefore, 55 participants constituted the full analysis sample. The CAR from weeks 9 to 24 was 63.6% (35/55; 95% confidence interval [CI]: 51.3% – 76.0%), while the CARs from weeks 9 to 12 and 9 to 52 were 76.4% (42/55; 95% CI: 65.2% – 87.5%) and 58.2% (32/55; 95% CI: 45.6% – 70.8%), respectively. These CARs were better than the results of the national survey on outpatient clinics with regard to smoking cessation under the National Health Insurance Program and that of the varenicline phase Ⅲ trial in Japan and the United States. There was only one participant who dropped out during the 12 weeks of the treatment period. This treatment decreased the scores related to withdrawal and craving symptoms. Conclusions: The addition of CASC to usual smoking cessation therapies resulted in high CARs, high patient retention rates, and improvement of cessation-related symptoms. The smartphone application CASC is a feasible and useful tool to help long-term continuous abstinence that can be combined with a standard smoking cessation treatment program. Clinical Trial: University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN ID: UMIN000020123).

23 January 2021 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
KKKazuomi Kario
Kazuomi Kario
ANAkihiro Nomura
Akihiro Nomura
AKAyaka Kato
Ayaka Kato
NHNoriko Harada
Noriko Harada
TTTomoyuki Tanigawa
Tomoyuki Tanigawa
KSKohta Satake
Kohta Satake
Hypertension is the most considerable but treatable risk factor for cardiovascular disease. Although physicians prescribe multiple antihypertensive drugs and promote lifestyle modifications, the real‐world blood pressure (BP) control rate remains poor. To improve BP target achievement, we developed a novel digital therapeutic—the HERB software system —to manage hypertension. Here, we performed a randomized pilot study to assess the safety and efficacy of the HERB system for hypertension. We recruited 146 patients with essential hypertension from March 2018 to March 2019. We allocated eligible patients to the intervention group (HERB system + standard lifestyle modification) or control group (standard lifestyle modification alone). The primary outcome was the mean change from baseline to 24 weeks in 24‐hour systolic BP (SBP) measured by ambulatory blood pressure monitoring (ABPM). The baseline characteristics in each group were well balanced; the mean age was approx. 57 years, and 67% were male. In the primary end point at 24 weeks, HERB intervention did not lower the mean change of 24‐hour SBP by ABPM compared with the controls (adjusted difference: −0.66 mmHg; p = .78). In an exploratory analysis focusing on antihypertensive drug‐naïve patients aged <65, the effects of the HERB intervention were significantly greater than the control for reducing 24‐hour SBP by ABPM at 16 weeks (adjusted difference: −7.6 mmHg; p = .013; and morning home SBP at 24 weeks (adjusted difference − 6.0 mmHg; p = .012). Thus, the HERB intervention did not achieve a primary efficacy end point. However, we observed that antihypertensive drug‐naïve adult hypertensive patients aged <65 years could be a potential HERB system‐effective target for further investigations of the efficacy of the system.

11 February 2019 in JMIR Research Protocols
Verified
Journal Article
Open access
ANAkihiro Nomura
Akihiro Nomura
HTHiroki Tateno
Hiroki Tateno
KMKatsunori Masaki
Katsunori Masaki
TMTomoyasu Muto
Tomoyasu Muto
SSShin Suzuki
Shin Suzuki
KFKoichi Fukunaga
Koichi Fukunaga
Background: Smoking cessation treatment programs have been widely available for patients with nicotine dependence. Despite intensive programs, the continuous abstinence rate (CAR) from weeks 9-12 is still about 50%. Recently, a smartphone app emerged as a novel tool for therapeutic interventions, including nicotine dependence. In this study, we developed “CureApp Smoking Cessation” (CASC), which consists of a smartphone app for patients and a Web-based patient management software for doctors with a mobile carbon monoxide (CO) checking device to improve the efficacy of the smoking cessation treatment. Objective: This study aims to evaluate whether the CASC app is effective for individuals with nicotine dependence in addition to standard smoking cessation programs. Methods: This will be a randomized, sham-controlled, open-label, multicenter trial. We will recruit participants with nicotine dependence, but are otherwise healthy adults. We will randomize and allocate participants 1:1 to the CASC treatment group or a control app group. Both groups will receive a 12-week standard smoking cessation program with pharmacotherapy and counseling. In addition, participants in the treatment group will have the CASC app installed on their smartphone, which will provide video tutorials, advice from an artificial intelligence nurse, a digital diary, and measure daily exhaled CO concentration. In contrast, the control group will have the control app installed on their smartphone, where all the functions that can potentially effect smoking cessation are removed. The primary outcome will be the biochemically validated CAR from weeks 9-24. The success of smoking cessation will be defined as self-reported continuous abstinence from weeks 9-24 and exhaled CO concentration ≤10 ppm both at weeks 12 and 24. The main secondary outcomes will be the CAR from weeks 9-12, weeks 9-52, and 7-day point prevalence abstinence at weeks 4, 8, 12, 24, and 52. Results: We will recruit 580 participants with nicotine dependence from October 2017 to September 2018 or until the recruitment process is complete. The final 52-week follow-up will be completed in October 2019. We expect all trial results to be available by the end of 2019. The trial is funded by CureApp, Inc. Conclusions: This is the first randomized controlled trial to evaluate the efficacy of CASC. We expect that CASC, in addition to standard smoking cessation programs, has a significantly higher CAR during weeks 9-24 than the control app. Trial Registration: University Hospital Medical Information Network Clinical Trials Registry UMIN000031589; https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000033555 International Registered Report Identifier (IRRID): DERR1-10.2196/12252

14 May 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
AKAyaka Kato
Ayaka Kato
TTTomoyuki Tanigawa
Tomoyuki Tanigawa
KSKohta Satake
Kohta Satake
ANAkihiro Nomura
Akihiro Nomura
Background: Smoking cessation helps extend a healthy life span and reduces medical expenses. However, the standard 12-week smoking cessation program in Japan has several notable problems. First, only 30% of participants complete this program. Second, participants may choose not to participate unless they have a strong motivation to quit smoking, such as health problems. Third, the program does not provide enough support during the period between clinical visits and after 12 weeks. Objective: This study examined the efficacy of the 24-week ascure program to address the problems of accessibility and continuous support. The program combines online mentoring, over-the-counter pharmacotherapy, and a smartphone app. Methods: Using a retrospective study design, we investigated data for 177 adult smokers who were enrolled in the ascure smoking cessation program between August 2017 and August 2018. The primary outcomes were continuous abstinence rates (CARs) during weeks 9-12 and weeks 21-24. To confirm smoking status, we performed salivary cotinine testing at weeks 12 and 24. We also evaluated the program adherence rate. Finally, we performed exploratory analysis to determine the factors associated with continuous abstinence at weeks 21-24 to provide insights for assisting with long-term continuous abstinence. Results: The CARs of all participants for weeks 9-12 and weeks 21-24 were 48.6% (95% CI 41.2-56.0) and 47.5% (95% CI 40.0-54.8), respectively. Program adherence rates were relatively high throughout (72% at week 12 and 60% at week 24). In the analysis of the factors related to the CAR at weeks 21-24, the number of entries in the app’s digital diary and number of educational videos watched during the first 12 weeks were significant factors. Conclusions: The ascure program achieved favorable CARs, and participants showed high adherence. Proactive usage of the smartphone app may help contribute to smoking cessation success in the long-term.